Femasys Stock News

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women

- 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization -

Penny stocks can be a treasure trove of investment opportunities, and the list of Most Active Penny Stocks is a good place to start looking. The downside is that many penny stocks are active for no go

Underlying prices exhibited a notable cooling trend, providing the Federal Reserve shows evidence of softer inflation. While Americans did indeed spend more on costly gasoline and services during the

Femasys (NASDAQ: FEMY ) stock is rocketing higher on Tuesday following approval from the Food and Drug Administration (FDA) for FemaSeed. FemaSeed is an infertility treatment that delivers sperm dire

Shares of biomedical firm Femasys (NASDAQ: FEMY ) more than doubled on Thursday. This followed an important intellectual property (IP) protection announcement.

After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate re

ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i

Femasys (FEMY) has appointed Dov Elefant to Chief Financial Officer ((CFO)), effective Feb

Femasys Inc (FEMY) shares closed today 13.0% lower than it did at the end of yesterday. The stock is currently down 27.9% year-to-date, down 76.6% over the past 12 months, and down 76.6% over the past five years. Today, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $3.44 and as low as $2.81 this week.Shares closed 79.6% below its 52-week high and 4.5% above its 52-week low.Trading volume this week was 65.6% lower than the 10-day average and 88.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -2194.6% The company's stock price performance over the past 12 months lags the peer average by -1706.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Femasys Inc (FEMY) shares closed today 10.2% lower than it did at the end of yesterday. The stock is currently down 70.7% year-to-date, down 70.7% over the past 12 months, and down 70.7% over the past five years. Today, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $4.77 and as low as $3.32 this week.Shares closed 74.4% below its 52-week high and 6.0% above its 52-week low.Trading volume this week was 141.3% higher than the 10-day average and 234.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Femasys Inc (FEMY) shares closed today 14.4% lower than it did at the end of yesterday. The stock is currently down 61.8% year-to-date, down 61.8% over the past 12 months, and down 61.8% over the past five years. Today, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 1.4%. Trading Activity Shares traded as high as $4.77 and as low as $3.70 this week.Shares closed 71.5% below its 52-week high and 5.9% above its 52-week low.Trading volume this week was 6.2% higher than the 10-day average and 22.1% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Zacks Investment Research downgraded shares of Femasys (NASDAQ:FEMY) from a buy rating to a hold rating in a report issued on Monday morning, Zacks.com reports. According to Zacks, Femasys Inc.is a biomedical company focused on transforming womens healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The []

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women''s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11 th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally i